Close-Up: Zealand Pharma's Treatment for Type-2 Diabetes Print E-mail
By Staff and Wire Reports   
Monday, 09 July 2012 08:10

Zealand Pharma (CPH:ZEAL) (OTC: ZLDPF) President and CEO Dr. David Solomon details timeframes in the development of lixisenatide, a treatment for type-2 diabetes licensed to Sanofi (NYSE:SNY), in this video interview.



“We’ve had a terrific partnership with [Sanofi] since 2003. They’ve advanced this through ten Phase III studies, 38 countries, 400 sites, and over 4300 patients , and we’re very pleased to report that the results of all those ten trials have been positive to date,” says Solomon. Currently lead by Novo Nordisk’s (NYSE:NVO) Victoza and Amylin’s (NASDAQ:AMLN) exenatide products, lixisenatide sets itself apart in this growing GLP-1 market ($6B by 2017) with good glycemic control and weight-loss - often difficult for diabetes patients. They hope to market the treatment as a monotherapy and also as a combination product with leading global insulin Lantus.

Solomon says Zealand is also seeking partnerships for some of their 11 early-stage pipeline candidates. He discusses implications of the company’s balance sheet and Zealand’s financial outlook for the next few years as they focus on novel poly-pharmacological approaches to diabetes treatment.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter